<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03422614</url>
  </required_header>
  <id_info>
    <org_study_id>Patho_PID</org_study_id>
    <nct_id>NCT03422614</nct_id>
  </id_info>
  <brief_title>Pathophysiology of Inborn Immunodeficiencies</brief_title>
  <official_title>Pathophysiologie Angeborener Immundefekte</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The pathophysiology of primary immunodeficiencies (PID), which encompass a broad range of
      different diseases with susceptibility to infection and/or a deregulated inflammatory
      response, is poorly understood. Available treatments are often not specific for a distinct
      target and might be associated with side effects. To elucidate pathophysiology of different
      PIDs, stool, urine, blood, tissue biopsies and/or bone marrow will be collected and analysed
      for anti-microbial activity and inflammatory response. In a second step, targeted treatment
      for different PIDs might be developed preclinically and ex vivo according to underlying
      pathophysiology.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2015</start_date>
  <completion_date type="Anticipated">July 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Characterisation of cellular phenotype in different PIDs</measure>
    <time_frame>immediately after sampling of biological specimen or up to 10 years later from frozen samples</time_frame>
    <description>Immune cell subsets will be analysed for Surface marker Expression or cell activation pathways</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Characterisation of functional phenotype in different PIDs</measure>
    <time_frame>immediately after sampling of biological specimen or up to 10 years later from frozen samples</time_frame>
    <description>Immune cell subsets will be analysed for cytokine production or cell activation pathways</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Identification of potential targets for pathophysiology-specific treatment, or for curative treatment such as gene therapy for different PIDs ex vivo</measure>
    <time_frame>immediately after sampling of biological specimen or up to 10 years later from frozen samples</time_frame>
    <description>Targets for development of new Treatment for PID identfied by Primary outcome analyses (see above) can be pathways, Surface marker Expression or cytokine production. Therefore new Treatment developed might consist of medication interfering with cell activation pathways, cytokine production (e.g. inhibitory antibodies against specific cytokines) or Surface marker Expression (e.g. inhibitory or stimulatory ligands for certain cell Surface receptors)</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Primary Immune Deficiency Disorder</condition>
  <arm_group>
    <arm_group_label>Patient</arm_group_label>
    <description>Patients with Primary Immunodeficiency</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Healthy Controls</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Diagnostic Test</intervention_name>
    <description>Characterisation of cellular and functional phenotype in different PIDs</description>
    <arm_group_label>Patient</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with PID and healthy controls of all ages might be tested, recruitment is in a
        tertiary care hospital setting
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of an inborn error of immunity (primary immunodeficiency, PID)

          -  Clinically healthy (non-age matched) volunteer

        Exclusion Criteria:

          -  exclusion of an inborn error of immunity

          -  secondary immunodeficiency

          -  refusal to enter the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janine Reichenbach, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Children's Hospital, Zurich</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Janine Reichenbach, Prof. Dr.</last_name>
    <phone>+41442667311</phone>
    <email>janine.reichenbach@kispi.uzh.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ulrich Siler, PD Dr.</last_name>
    <phone>+41442667311</phone>
    <email>ulrich.siler@kispi.uzh.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Children's Hospital Zurich</name>
      <address>
        <city>Zurich</city>
        <zip>8032</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janine Reichenbach, Prof. Dr.</last_name>
      <phone>+41442667311</phone>
      <email>janine.reichenbach@kispi.uzh.ch</email>
    </contact>
    <contact_backup>
      <last_name>Ulrich Siler, PD Dr.</last_name>
      <phone>+41442667311</phone>
      <email>ulrich.siler@kispi.uzh.ch</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2018</study_first_submitted>
  <study_first_submitted_qc>January 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2018</study_first_posted>
  <last_update_submitted>January 29, 2018</last_update_submitted>
  <last_update_submitted_qc>January 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Zurich</investigator_affiliation>
    <investigator_full_name>Janine Reichenbach</investigator_full_name>
    <investigator_title>Co-Head Division Immunology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>We are planning to share IPD in the form of Scientific publications in peer-reveiwed journals and communications at Scientific meetings</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

